Updated on 15 June 2026
Evidence-led healthtech, medicines workflow and pilot-readiness
Founder, CEO at NEUVIOR® - UK Pharma Infrastructure
London, United Kingdom
About
commercialisation.
I’m building PHARMORIS around a simple problem: healthcare organisations often have medicines signals, dashboards and committee discussions, but the difficult part is converting those signals into owned actions, credible evidence, accountable review, blocker resolution and value tracking.
Areas I’m actively working through include:
• medicines optimisation workflow
• ActionCase and evidence-pack design
• source provenance and auditability
• human review and AI-assist boundaries
• pilot-readiness evidence
• clinical-safety awareness
• DTAC/DCB/DSPT readiness thinking
• buyer-safe healthtech positioning
• evidence-to-policy and evidence-to-procurement routes
• investor-grade pilot evidence
I’m very open to comparing notes with people working on regulation, standards, clinical safety, NHS innovation, medicines, AI assurance, medtech commercialisation and public-interest innovation.
Organisation
Similar opportunities
Investment
PHARMORIS £1.4m seed round - evidence-led medicines workflow platform
- Series A | Scale business
- Seed funding | Get business started
Varun Cruz
Founder, CEO at NEUVIOR® - UK Pharma Infrastructure
London, United Kingdom
Project cooperation
PHARMORIS pilot-readiness cooperation: evidence, standards and NHS adoption
- Market Access
- Strategic Partnership
- Dissemination project results
Varun Cruz
Founder, CEO at NEUVIOR® - UK Pharma Infrastructure
London, United Kingdom
Product
PHARMORIS - governed medicines action layer
- Buyer
- License partner
- Investment/Finance
- Re-Seller/Wholesaler
Varun Cruz
Founder, CEO at NEUVIOR® - UK Pharma Infrastructure
London, United Kingdom